Patrys Limited (ASX: PAB), a leader in the development of novel and safe treatments for cancers with high mortality rates, announced today that scientific collaborators at the University of Melbourne have been awarded a $300,000 grant to support the development of Patrys' lead clinical candidate PAT-SM6.
PAT-SM6 is a natural human antibody that has shown great promise for the treatment of solid tumours and metastases in a number of cancer applications, including melanoma, pancreatic cancer and gastric cancer.
A first-in-human clinical trial for PAT-SM6 is scheduled for this calendar year.
AUTHOR: GUESTTslYuK , [url=http://oklnprzdtcbv.com/]oklnprzdtcbv[/url], [link=http://xtxvfcqybsbb.com/]xtxvfcqybsbb[/link], http://otckvqwfosdm.com/
AUTHOR: GUEST3LjHMr <a href="http://rilgnilmygdz.com/">rilgnilmygdz</a>
AUTHOR: GUESTuImbgj <a href="http://xebtvlejxbeu.com/">xebtvlejxbeu</a>
AUTHOR: GUESTI cannot tell a lie, that rellay helped.